Opportunities in somatostatin research: biological, chemical and therapeutic aspects
G Weckbecker, I Lewis, R Albert, HA Schmid… - Nature reviews Drug …, 2003 - nature.com
G Weckbecker, I Lewis, R Albert, HA Schmid, D Hoyer, C Bruns
Nature reviews Drug discovery, 2003•nature.comSomatostatins—also known as somatotropin-release inhibiting factors (SRIFs)—are a family
of cyclopeptides that have broad inhibitory effects on the secretion of hormones such as
growth hormone, insulin and glucagon. These effects have formed the basis for the clinical
use of SRIF analogues in the treatment of acromegaly and endocrine tumours. The
discovery of the five SRIF receptor subtypes in the 1990s further enhanced our
understanding of the biological roles of SRIFs, and paved the way for new therapeutic …
of cyclopeptides that have broad inhibitory effects on the secretion of hormones such as
growth hormone, insulin and glucagon. These effects have formed the basis for the clinical
use of SRIF analogues in the treatment of acromegaly and endocrine tumours. The
discovery of the five SRIF receptor subtypes in the 1990s further enhanced our
understanding of the biological roles of SRIFs, and paved the way for new therapeutic …
Abstract
Somatostatins — also known as somatotropin-release inhibiting factors (SRIFs) — are a family of cyclopeptides that have broad inhibitory effects on the secretion of hormones such as growth hormone, insulin and glucagon. These effects have formed the basis for the clinical use of SRIF analogues in the treatment of acromegaly and endocrine tumours. The discovery of the five SRIF receptor subtypes in the 1990s further enhanced our understanding of the biological roles of SRIFs, and paved the way for new therapeutic opportunities. Here we review recent advances in SRIF biology, the chemistry of SRIF agonists and antagonists, and the therapeutic potential of such compounds in a wide range of established and novel indications.
nature.com